Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 3/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.30 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534074 | 0.82 | GFER (0.34) | KDM4EARCTSKKMT2AGFER | |
| SCHEMBL533297 | 0.82 | CTSK (0.39) | KDM4EARCTSKKMT2AGFER | |
| SCHEMBL533223 | 0.76 | KDM4E (0.40) | KDM4EARKMT2AGFERLMNA | |
| SCHEMBL533597 | 0.75 | IRAK4 (0.31) | KDM4EAR | |
| SCHEMBL533221 | 0.72 | CYP3A4 (0.51) | KDM4EKMT2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL533149 | 0.72 | GFER (0.41) | KDM4EARKMT2AGFERLMNA | |
| SCHEMBL2155406 | 0.72 | CYP19A1 (0.40) | KDM4EARKMT2AGFERLMNA | |
| SCHEMBL533201 | 0.71 | IDH1 (0.36) | IDH1KDM4EARKMT2ALMNA | |
| SCHEMBL533541 | 0.68 | SHMT2 (0.36) | KDM4EAR | |
| SCHEMBL533679 | 0.68 | GFER (0.32) | KDM4EGFERLMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-102448940-B | For the medical composition of glaucomatous treatment or prevention | UBE INDUSTRIES, LTD. (JP) | 2015-10-21 | — | — | CN | disclosed |
| CN-103965099-A | Pyridylaminoacetic Acid Compound | UBE INDUSTRIES | 2014-08-06 | — | — | CN | disclosed |
| CN-101970410-B | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2014-06-25 | — | — | CN | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | IDH1 3942/4885KDM4E 2779/4885AR 680/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | IDH1 4099/4885KDM4E 2804/4885AR 799/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | IDH1 277/4885KDM4E 3706/4885AR 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.